VS-041 — HFpEF (Pfizer)
Heart Failure with Preserved Ejection Fraction (HFpEF)
Sponsor: Pfizer · Pfizer Protocol VS-041-102
About this study
Investigational therapy targeting cardiac structural remodeling in heart failure with preserved ejection fraction (HFpEF).
To evaluate the safety and effect of an investigational therapy targeting cardiac structural remodeling in adults with HFpEF.
Study details
- Sponsor
- Pfizer
- Protocol
- Pfizer Protocol VS-041-102
- Phase
- Phase 2
- Indication
- Heart Failure with Preserved Ejection Fraction (HFpEF)
- Status
- Currently Recruiting
High-level eligibility
- Adults 40–80 with NYHA Class II–III HFpEF
- LVEF ≥ 50%
- Elevated NT-proBNP
Eligibility above is a summary. Final qualification is determined by the study protocol and a screening visit at amavita Heart and Vascular Health®.
I'm a sponsor / CRO →
Discuss enrollment, capacity, and operational fit.
I might be eligible — call (786) 703-5941 →
Free, no-obligation pre-screen in English / Spanish / Haitian Creole.
Participation in any clinical trial is voluntary and requires written informed consent reviewed by an Institutional Review Board (IRB) before any study procedure. You may withdraw at any time. Website content is informational and is not a substitute for medical advice from a licensed clinician.